Seven scientific abstracts, one thematic session and one plenary session related to Stockholm3 have been accepted for presentation at the upcoming 38th European Association of Urology (EAU) meeting that will be held March-10-13 in Milan, Italy.
The accepted presentations, outlined below, cover topics such as validation of Stockholm3 in new populations, experience from use of Stockholm3 in clinical practice and early mortality data from the original population based-Stockholm3 screening.
|Abstract title||Presenting author, city||Session||Date/location|
|Prostate biopsies can be omitted in most patients with a positive Stockholm3-test and a negative prostate magnetic resonance imaging||M.N. Vigmostad, Stavanger (NO)||Abstract session 04||Friday March 10th, 15:15-16:45|
|External validation of Stockholm3 in a retrospective German clinical cohort||D. Tilki, Hamburg (DE)||Abstract session 04||Friday March 10th, 15:15-16:45|
|The Capio S:t Göran model for prostate cancer diagnosis using Stockholm3, magnetic resonance imaging and targeted biopsies||T. Palsdottir, Solna (SE)||Abstract session 04||Friday March 10th, 15:15-16:45|
|Update on current screening trials – STHLM3||T. Nordström, Stockholm (SE)||Plenary session, Yellow area, eURO Auditorium 1||Sunday March 12th, 8:00-10:30|
|Experiences from the Swedish population based organised prostate cancer testing programme||O. Bratt, Gothenburg (SE)||Thematic session, Yellow area, eURO Auditorium 1||Sunday March 12th, 13:45-15:15|
|The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up||C. Micoli, Stockholm (SE)||Abstract session 48||Sunday March 12th, 17:30-19:00|
|Repeat prostate cancer screening using prostate-specific antigen, a multiplex blood-test and magnetic resonance imaging: 2nd screening round outcomes of STHLM3-MRI||T. Nordström, Stockholm (SE)||Abstract session 48||Sunday March 12th, 17:30-19:00|
|Prospective multicenter validation of the Stockholm-3 (STHLM3) test in a Middle European population||A. Elyan, Basel (CH)||Abstract session 48||Sunday March 12th, 17:30-19:00|
|External validation of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and comparison to Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort||T. Palsdottir, Solna (SE)||Abstract session 48||Sunday March 12th, 17:30-19:00|
“The interest for Stockholm3 continues to grow in Europe and it is very encouraging to see external validation of the algorithm in countries outside Scandinavia, 5-year results after incorporating Stockholm3 into a clinical care system in the Stockholm community and six-year interim data evaluating prostate cancer mortality after one-time screening using Stockholm3. This further supports evidence for use of Stockholm3 as a reliable decision tool in selection of men for prostate cancer testing,” says Hari Vigneswaran MD, Director of Medical Affairs at A3P Biomedical.
The full abstracts are available today on the EAU23 virtual platform (here).